A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.
JNCCN Journal of the National Comprehensive Cancer Network.
Times cited: 8
Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: A systematic review and pooled analysis.
Journal of Clinical Oncology.
Times cited: 166